Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States
This real-world study demonstrates that for patients with HR+/HER2- mBC, chemotherapy provides relatively limited survival benefit which decreases with each additional chemotherapy line, and highlights the need for improved treatment options.
Authors
- Anvay Shah (ORCID: https://orcid.org/0000-0002-1227-2551)
- Kathy Fraeman
- W. Verret
- I. Ntalla
- Kevin Punie (ORCID: https://orcid.org/0000-0002-1162-7963)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Lisa A. Carey (ORCID: https://orcid.org/0000-0003-2388-4649)
- Michael Stokes (ORCID: https://orcid.org/0000-0002-1822-6214)
- Allison W. Kurian (ORCID: https://orcid.org/0000-0002-6175-9470)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- N. Sjekloca
- M K Rehnquist
Institutions
- Ithaka Harbors (US)
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- GZA Ziekenhuizen Campus Sint-Augustinus (BE)
- Gilead Sciences (United Kingdom) (GB)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- UNC Lineberger Comprehensive Cancer Center
- Stanford University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103691
- Citations
- 18
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 7.54
Funders
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- Memorial Sloan-Kettering Cancer Center
- Genentech